Fidaxomicin + Vancomycin + Matching Placebo to Fidaxomicin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridium Infections
Conditions
Clostridium Infections, Diarrhea
Trial Timeline
May 2, 2006 → Aug 21, 2008
NCT ID
NCT00314951About Fidaxomicin + Vancomycin + Matching Placebo to Fidaxomicin
Fidaxomicin + Vancomycin + Matching Placebo to Fidaxomicin is a phase 3 stage product being developed by Merck for Clostridium Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00314951. Target conditions include Clostridium Infections, Diarrhea.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00314951 | Phase 3 | Completed |
Competing Products
20 competing products in Clostridium Infections